AKBA - Akebia Therapeutics, Inc. - Alternativkedja

Akebia Therapeutics, Inc.
US ˙ NasdaqCM ˙ US00972D1054

Utgång
Calls för June 04, 2026
Kontrakt Strike Bud Fråga Senaste Volym OI IV Delta Gamma Theta Theta Rho
AKBA20260618C00000500 0.50 0.10 0.85 0.00 0 6 0.00% 0.00 0.00 0.00 0.00 0.00
AKBA20260618C00001000 1.00 0.00 0.10 0.09 5 289 74.15% 0.49 2.78 -0.00 0.00 0.00
AKBA20260618C00001500 1.50 0.00 0.05 0.01 1 115 182.04% 0.16 0.69 -0.00 0.00 0.00
AKBA20260618C00002000 2.00 0.00 0.05 0.00 0 201 257.39% 0.13 0.42 -0.00 0.00 0.00
AKBA20260618C00003000 3.00 0.00 0.25 0.00 0 0 411.95% 0.17 0.31 -0.01 0.00 0.00
AKBA20260618C00004000 4.00 0.00 0.75 0.00 0 1 0.00% 0.00 0.00 0.00 0.00 0.00
AKBA20260618C00005000 5.00 0.00 0.75 0.00 0 3 0.00% 0.00 0.00 0.00 0.00 0.00
Puts för June 04, 2026
Kontrakt Strike Bud Fråga Senaste Volym OI IV Delta Gamma Theta Theta Rho
AKBA20260618P00000500 0.50 0.00 0.05 0.00 0 1 300.95% -0.07 0.24 -0.00 0.00 0.00
AKBA20260618P00001000 1.00 0.00 0.20 0.12 1 1 118.83% -0.48 1.74 -0.00 0.00 -0.00
AKBA20260618P00001500 1.50 0.20 0.85 0.00 0 9 318.30% -0.64 0.61 -0.01 0.00 -0.00
AKBA20260618P00002000 2.00 0.65 1.35 0.00 0 1 708.72% -0.42 0.28 -0.02 0.00 -0.00
AKBA20260618P00003000 3.00 1.65 2.40 0.00 0 0 296.75% -0.95 0.19 -0.00 0.00 -0.00
AKBA20260618P00004000 4.00 2.60 3.60 0.00 0 0 549.03% -0.78 0.28 -0.01 0.00 -0.00
AKBA20260618P00005000 5.00 3.60 4.60 0.00 0 0 600.35% -0.78 0.25 -0.01 0.00 -0.00
How Much do you Like Fintel?
Please share your opinion of our service!
Excellent Bad
Other Listings
DE:AX9 0,81 €
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista